AZN
AstraZenecaFNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive late-stage readouts and a favorable FY2025 beat lead to multiple expansion and re-rating toward the upper analyst range within 12 months.
Posture
Defensive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Late-stage clinical trial failure or delay
Momentum
35
Value
62
Sentiment
5
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $97.65 · Bull $123.69 · Bear $79.98
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-24 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $220.99
Why
Momentum35 · Δ7d +4.8
Value62 · Δ7d +0.5
Sentiment5 · Δ7d +4.5
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
35
34% active weight
Current posture
7d trendImproving
Δ7d
+4.8
Δ21d
+12.7
Value
62
32% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
+0.7
Sentiment
5
33% active weight
Current posture
7d trendImproving
Δ7d
+4.5
Δ21d
+4.5
Why this grade
Composite grade F. Momentum 34.8 / Value 62.3 / Sentiment 5.2
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$280.26B
Beta
0.86
Shares Out
1.55B
P/E (TTM)
29.9
P/S (TTM)
4.81
P/FCF (TTM)
60.77
Rev YoY
+12.0%
EPS YoY
+77.4%
Gross Margin
+81.9%
Op Margin
+22.0%
Net Debt
$24.64B
Current Ratio
0.88
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology